JP2004530114A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004530114A5 JP2004530114A5 JP2002566656A JP2002566656A JP2004530114A5 JP 2004530114 A5 JP2004530114 A5 JP 2004530114A5 JP 2002566656 A JP2002566656 A JP 2002566656A JP 2002566656 A JP2002566656 A JP 2002566656A JP 2004530114 A5 JP2004530114 A5 JP 2004530114A5
- Authority
- JP
- Japan
- Prior art keywords
- sepcr
- measured
- patient
- levels
- immunoassay
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27006601P | 2001-02-20 | 2001-02-20 | |
| US10/028,741 US7169573B2 (en) | 2001-02-20 | 2001-12-20 | Method for monitoring coagulability and hypercoagulable states |
| PCT/US2002/005023 WO2002066981A2 (en) | 2001-02-20 | 2002-02-19 | Monitoring soluble endothelial protein c receptor levels in anticoagulant therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004530114A JP2004530114A (ja) | 2004-09-30 |
| JP2004530114A5 true JP2004530114A5 (https=) | 2005-12-22 |
Family
ID=26704034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002566656A Withdrawn JP2004530114A (ja) | 2001-02-20 | 2002-02-19 | 抗凝固剤治療における可溶性内皮プロテインｃレセプターレベルのモニタリング |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7169573B2 (https=) |
| EP (1) | EP1368661A2 (https=) |
| JP (1) | JP2004530114A (https=) |
| AU (1) | AU2002245474B2 (https=) |
| CA (1) | CA2438811A1 (https=) |
| WO (1) | WO2002066981A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2941594C (en) * | 2002-12-20 | 2021-07-06 | Celera Corporation | Genetic polymorphisms of the protein receptor c (procr) associated with myocardial infarction, methods of detection and uses thereof |
| US7906117B2 (en) * | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US8404235B2 (en) * | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
| US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
| US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US20090238825A1 (en) * | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| HUE032563T2 (en) | 2007-05-21 | 2017-09-28 | Alderbio Holdings Llc | Antibodies to IL-6 and their use |
| KR20170036814A (ko) * | 2007-05-21 | 2017-04-03 | 앨더바이오 홀딩스 엘엘씨 | 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체 |
| US8277804B2 (en) * | 2008-05-21 | 2012-10-02 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| CA2744400C (en) * | 2008-11-25 | 2019-01-15 | Alder Biopharmaceuticals, Inc. | Antibodies to il-6 and use thereof |
| US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
| US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| FR2948666A1 (fr) | 2009-07-30 | 2011-02-04 | Univ Paris Curie | Methode de diagnostic d'un cancer et de determination de la severite d'un cancer chez un individu |
| WO2011066374A2 (en) | 2009-11-24 | 2011-06-03 | Alder Biopharmaceuticals, Inc. | Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
| US9304134B2 (en) | 2010-11-23 | 2016-04-05 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of anemia |
| EP3673870A3 (en) * | 2018-11-09 | 2020-09-09 | Universite Paris Descartes | Bioprosthetic tissues and heart valves coated with epcr |
| MX2022004558A (es) * | 2019-10-17 | 2023-03-02 | Nova Biomedical Corp | Aparato de ensayo de coagulacion y metodos del mismo. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5695993A (en) | 1994-08-12 | 1997-12-09 | Oklahoma Medical Research Foundation | Cloning and regulation of an endothelial cell protein C/activated protein C receptor |
| WO2000007012A1 (en) * | 1998-07-31 | 2000-02-10 | Carroll Wallace E | Method and apparatus for determining anticoagulant therapy factors |
| US5804392A (en) | 1997-06-27 | 1998-09-08 | Oklahoma Medical Research Foundation | Diagnostic assays using soluble endothelial cell protein C/activated protein C receptor |
| US5935802A (en) * | 1998-08-10 | 1999-08-10 | Evanston Northwestern Healthcare Research Institute | Method of assaying a blood sample for prothrombin |
-
2001
- 2001-12-20 US US10/028,741 patent/US7169573B2/en not_active Expired - Fee Related
-
2002
- 2002-02-19 EP EP02713636A patent/EP1368661A2/en not_active Withdrawn
- 2002-02-19 AU AU2002245474A patent/AU2002245474B2/en not_active Ceased
- 2002-02-19 WO PCT/US2002/005023 patent/WO2002066981A2/en not_active Ceased
- 2002-02-19 JP JP2002566656A patent/JP2004530114A/ja not_active Withdrawn
- 2002-02-19 CA CA002438811A patent/CA2438811A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004530114A5 (https=) | ||
| JP7246559B2 (ja) | 凝固分析を使用した抗凝固剤の検出および分類 | |
| Hans et al. | The place of viscoelastic testing in clinical practice | |
| Taylor | Protein biomarkers of periodontitis in saliva | |
| AU2008201621B8 (en) | A method for predicting the presence of haemostatic dysfunction in a patient sample | |
| Karabudak et al. | Inflammation and hypercoagulable state in adult psoriatic men | |
| Toorop et al. | The relationship between DOAC levels and clinical outcomes: the measures tell the tale | |
| CA2380622C (en) | A method for predicting the presence of haemostatic dysfunction in a patient sample | |
| US11821905B2 (en) | Biomarkers of vascular disease | |
| Okada et al. | Prognostic Value of Prothrombin Time International Normalized Ratio in Acute Decompensated Heart Failure–A Combined Marker of Hepatic Insufficiency and Hemostatic Abnormality– | |
| Samama | Which test to use to measure the anticoagulant effect of rivaroxaban: the anti-factor Xa assay | |
| Eisen et al. | Inflammation and future risk of symptomatic heart failure in patients with stable coronary artery disease | |
| EP3658920A1 (en) | Methods and devices for detection of anticoagulants in plasma and whole blood | |
| Harenberg et al. | Determination of direct oral anticoagulants from human serum samples | |
| Ferreira et al. | Thrombin generation assay as a biomarker of cardiovascular outcomes and mortality: a narrative review | |
| Khizroeva et al. | Laboratory monitoring of COVID-19 patients and importance of coagulopathy markers | |
| Lemańska-Perek et al. | Plasma and cellular forms of fibronectin as prognostic markers in sepsis | |
| Karpińska et al. | A prothrombotic state and denser clot formation in patients following acute limb ischemia of unknown cause | |
| Ali et al. | Alterations in D-Dimer, Prothrombin time and activated partial thromboplastin time as thrombogenesis activity markers in patients with acute myocardial infarction | |
| Bessa et al. | Haptoglobin gene polymorphism in type 2 diabetic patients with and without nephropathy: An Egyptian study | |
| Kartal Durmazlar et al. | Homocysteine May Involve in the Pathogenesis of Behcet′ s Disease by Inducing Inflammation | |
| Honsawek et al. | Soluble receptor for advanced glycation end products and liver stiffness in postoperative biliary atresia | |
| Brophy et al. | Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction | |
| Pottier et al. | D-Dimers, Thrombin—Antithrombin Complexes, and Risk Factors for Thromboembolism in Hospitalized Patient | |
| Amiral | State-of-the-Art Review: Molecular Markers in Thrombosis and Hemostasis |